Back to today’s briefing

Story perspectives

Novo Nordisk Shares Slip 6% Despite Raised Outlook, Wegovy Miss

8/5/2026

35 7 Full Breakdown

Summary

Story summary

Novo Nordisk's shares fell 6% after it raised its 2026 outlook but missed Wegovy pill expectations and reported a weak CagriSema trial.
Adjusted 2026 sales and profit are seen down 6% to flat at rates, narrowing the prior 4%-12% decline range.
Wegovy oral pill Q2 sales were 3.22 billion Danish crowns, while CagriSema matched tirzepatide on weight loss but not on blood-sugar, prompting analysts to call it no better than Lilly's.

1 of 1

Story summary

Novo Nordisk's shares fell 6% after it raised its 2026 outlook but missed Wegovy pill expectations and reported a weak CagriSema trial.
Adjusted 2026 sales and profit are seen down 6% to flat at rates, narrowing the prior 4%-12% decline range.
Wegovy oral pill Q2 sales were 3.22 billion Danish crowns, while CagriSema matched tirzepatide on weight loss but not on blood-sugar, prompting analysts to call it no better than Lilly's.